Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: Pharmacokinetics, bioactivity, toxicity and chemistry

Journal of Nuclear Medicine

Volumn 40, Issue 1, 1999, Pages 166-176

  Nikula, Tuomo K ^b   McDevitt, Michael R ^b   Finn, Ronald D ^b   Wu, Chuanchu ^b   Kozak, Robert W ^b   Garmestani, Kayhan ^b   Brechbiel, M W ^b   Curcio, Michael J ^b   Pippin, C Greg ^b   Tiffany Jones, L ^b   Geerlings Sr , Maurits W ^b   Apostolidis, Christos ^b   Molinet, Roger ^b   Geerlings Jr , Maurits W ^b   Gansow, Otto A ^b   Scheinberg, David A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

particles; 212Bi; 213Bi; CHX A DTPA; HuM195; M195; Monoclonal antibodies

Indexed keywords

BISMUTH DERIVATIVE; MONOCLONAL ANTIBODY M 195; PENTETIC ACID DERIVATIVE;

ALPHA RADIATION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER RADIOTHERAPY; ISOTOPE LABELING; LEUKEMIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY;

ALPHA PARTICLES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; HL-60 CELLS; HUMANS; MICE; MICE, INBRED BALB C; PENTETIC ACID; RADIOIMMUNOTHERAPY; RECOMBINANT PROTEINS;

EID: 0032898445     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Kaminski MS, Zasadny KR, Francis IR, et al. Radioimmunotherapy of B-cell lymphoma with [I-131]anti-B1 (anti-CD20) antibody. N Engl J Med. 1993;329: 459-465.
2. Press OW, Early JF, Badjer CC, et al. Treatment of refractory non-Hodgkins lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J Clin Oncol. 1988;7: 1027-1399.
3. Schwartz MA, Lovett DR, Redner A, et al. Dose-escalation trial of M195 labeled with iodine-131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. J Clin Oncol. 1993;11:294-303.
4. Kassis AI, Adelstein SJ, Haycock C, Sastry KRS. Radiotoxicity of Se-75 and S-35. Theory and application to a cellular model. Radiat Res. 1980;84:407-425.
5. Daghighian F, Barendswaard E, Welt S, et al. Enhancement of radiation dose to the nucleus by vesicular internalization of iodine-125 labeled A33 monoclonal antibody. J Nucl Med. 1996;37:1052-1057.
6. Gansow OA, Atcher RW, Link DC, et al. Generator-produced Bi-212 chelated to chemically modified monoclonal antibody for use in radiotherapy. In: Knapp FF, Butler TA, eds. Radionuclide Generators: New Systems for Nuclear Medicine Application. Symposium Series no. 241. Washington, DC: American Chemical Society; 1984:215-227.
7. Macklis RM, Lin JY, Beresford B, Atcher RW, Hines JJ, Humm JL. Cellular kinetics, dosimetry, and radiobiology of α-particle radioimmunotherapy: induction of apoptosis. Radiat Res. 1992;130:220-226.
8. Zweit J. Radionuclides and carrier molecules for therapy. Phys Med Biol. 1996;41:1905-1914.
9. Vaidyanathan G, Zalutsky MR. Targeted therapy using alpha emitters. Phys Med Biol. 1996;41:1915-1931.
10. Zalutsky MR, Schuster JM, Garg PK, Archer GE Jr, Dewhirst MW, Bigner DD. Two approaches for enhancing radioimmunotherapy: α-emitters and hyperthermia. Recent Results Cancer Res. 1996;141:101-112.
11. Zalutsky MR, Bigner DD. Radioimmunotherapy with α-particle emitting radioimmunoconjugates. Acta Oncol. 1996;35:373-379.
12. Vaughan ATM, Bateman WJ, Fisher DR. The in vivo fate of a At-211 labeled monoclonal antibody with known specificity in a murinc system. Int J Rad Oncol Biol Phys. 1982;8:1943-1946.
13. 2 fragments with the α-particle emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity. Proc Natl Acad Sci USA. 1989;86:7149-7153.
14. Langmuir VK, Atcher RA, Hines JJ, Brechbiel MW. Iodine-125-NRLU-10 kinetic studies and bismuth-212-NRLU-10 toxicity in LS174T nulticell spheroids. J Nucl Med. 1990;31:1527-1533.
15. Huneke RB, Pippin CG, Squire RA, Brechbiel MW, Gansow OA, Strand M. Effective α-particle-mediated radioimmunotherapy of murine leukemia. Cancer Res. 1992;52:5818-5820.
16. Kocher DC. In: Radioactive Decay Data Tables: A Handbook of Decay Data for Application to Radiation Dosimetry and Radiological Assessments. Springfield, VA: U.S. Department of Energy/Technical Information Center; 1981:61-67.
17. Wilbur DS. Potential use of alpha emitting radionuclides in the treatment of cancer. Antibody Immunoconj Radiopharm. 1991;4:85-97.
18. Atcher RN, Friedman AM, Hines JJ. An improved generator for the production of Bi-212 and Bi-212 from Ra-224. Appl Radiat Isot. 1988;39:283-286.
19. Geerlings MW, Kaspersen FM, Apostolidis C, Van Der Hout R. The feasibility of Ac-225 as a source of α-particles in radioimmunotherapy. Nucl Med Commun. 1993;14:121-125.
20. McDevitt MR, Nikula TN, Finn RD, et al. Bismuth labeled antibodies for therapy of leukemias, lymphomas, and carcinomas: preclinical studies [abstract]. Tumor Target. 1996;2:182.
21. Finn RD, McDevitt MR, Scheinberg DA, et al. Refinements and improvements for Bi-213 production and use as a targeted therapeutic radiopharmaceutical [abstract]. J Labelled Compounds Radiopharm. 1997;40:293.
22. Jurcic JG, McDevitt MR, Sgouros G. et al. Targeted alpha particle therapy for myeloid leukemias: a phase 1 trial of bismuth-213-HuM195 (anti-CD33) [abstract]. Blood. 1997;90(suppl):504a.
23. Sgouros G, Humm JL, McDevitt MR, et al. Bismuth-213 imaging: pre-clinical characterization of an alpha-particle emitting radionuclide [Abstract]. J Nucl Med. 1996;37:78P.
24. Sgouros G, Graham MC, Divgi CD, Larson SM, Scheinberg DA. Modeling and dosimetry of monoclonal antibody M195 (anti-CD33) in acute myelogenous leukemia. J Nucl Med. 1993;34:422-429.
25. Sgouros G, Erdi YE, Humm JL, et al. Pharmacokinetics and dosimetry of an alpha-particle emitter labeled anti-CD33 antibody ([Bi-213]HuM195) in patients with leukemia [Abstract]. J Nucl Med. 1997;38:231P.
26. Ballangrud AM, Humm JL, McDevitt MR, et al. Normal organ dosimetry of leukemia patients treated with HuM195 labeled with the alpha particle emitter bismuth-213 [abstract]. J Nucl Med. 1998;39:188P.
27. Scheinberg DA, Lowett J, Divgi CD, et al. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide J Clin Oncol. 1991;9:478-483.
28. Caron PC, Jurcic JG, Scott AM, et al. A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity. Blood. 1994;83:1760-1768.
29. Brechbiel MW, Pippin CG, McMurry TJ, et al. An effective chelating agent for labeling of monoclonal antibody with Bi-212 for α-particle mediated radioimmunotherapy. J Chem Soc Chem Commun. 1991:1169-1170.
30. Brechbiel MW, Gansow OA. Synthesis of C-functionalized trans-cyclohexyldiethylenetriaminepentaacetic acids for labeling of monoclonal antibodies with the bismuth-212 α-particle emitter. J Chem Soc Perkin Trans. 1992;1173-1178.
31. Junghans RP, Dobbs D, Brechbiel MW, et al. Pharmacokinetics and bioactivity of 1,4,7,10-tetra-azacyclododecane N,N′,N″,N‴-tetraacetic acid (DOTA)-bismuth-conjugated anti-Tac antibody for α-emitter (Bi-212) therapy. Cancer Res. 1993;53:5683-5689.
32. Caron PC, Co MS, Bull MK, Avdalovic NM, Queen C, Scheinberg DA. Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Res. 1992;52:6761-6767.
33. Co MS, Avdalovic NM, Caron PC, Avdalovic MV, Scheinberg DA, Queen C. Chimeric and humanized antibodies with specificity for the CD33 antigen. J Immunol 1992;148:1149-1154.
34. Tanimoto M, Scheinberg DA, Cordon-Cardo C, Huie D, Clarkson BD, Old LJ. Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195. Leukemia. 1989;3:339-348.
35. Juric JG, Scheinberg DA. Monoclonal antibody therapy of myeloid leukemias. Principles Practice Oncol Updates. 1995;9:1-12.
36. Scheinberg DA, Tanimoto M, McKenzie S, Strife A, Old LJ, Clarkson BD. Monoclonal antibody M195: a diagnostic marker for acute myelogenous leukemia. Leukemia. 1989;3:440-445.
37. Co MS, Scheinberg DA, Avdalovic NM, et al. Genetically engineered deglycosylation of the variable domain increases the affinity of an anti-CD33 monoclonal antibody. Mol Immunol. 1993;30:1361-1367.
38. Nikula TK, Curcio MJ, Brechbiel MW, Gansow OA, Finn RD, Scheinberg DA. A rapid, single vessel method for preparation of clinical grade ligand conjugated monoclonal antibodies. Nucl Med Biol. 1995;22:387-390.
39. Mirzadeh S, Brechbiel MW, Atcher RW, Gansow OA. Radiometal labeling of immunoproteins: covalent linkage of 2-(4-isothiocyanatobenzyl)diethylenetriaminepentaacetic acid ligands to immunoglobulin. Bioconjug Chem. 1990; 1:59-65.
40. Pippin CG, Parker TA, McMurry TJ, Brechbiel MW. Spectrophotometric method for the determination of a bifunctional DTPA ligand in DTPA-monoclonal antibody conjugates. Bioconjug Chem. 1992;3:342-345.
41. Ruegg CL, Anderson-Berg WT, Brechbiel MW, Mirzadeh S, Gansow OA, Strand M. Improved in vivo stability and tumor targeting of bismuth labeled antibody. Cancer Res. 1990;50:4221-4226.
42. Van Geel JNC, Fuger J, Koch L. Verfahren zur erzeugung von actinium-225 und wismuth-213. European Patent no. 0 443 479 BI; 1994.
43. Van Geel JNC. Methods for the production of Ac-225 and Bi-213 for alpha immunotherapy. ITU Annual Report 1995-(EUR 16368)-Basic Actinide Research. Karlsruhe, Germany: Joint Research Centre; 1995:55-56.
44. Boll RA, Mirzadeh S, Kennel SJ, DePaoli DW, Webb OF. Bi-213 for alpha-particle mediated radioimmunotherapy. J Labelled Compounds Radiopharm. 1997;40:341-343.
45. Spivakov BY, Stoyanov ES, Gribov LA, Zolotov YA. Raman laser spectroscopic studies of bismuth(III) halide complexes in aqueous solutions. J Inorg Nucl Chem. 1979;14:453-455.
46. Zamora PO, Sass K, Cardillo AS, et al. Affinity thin-layer chromatography test of the immunoreactive fraction of radiolabeled antibodies. BioTechniques. 1994;16: 306-311.
47. Pippin CG, Gansow OA, Bechbiel MW, et al. Recovery of Bi-213 from an Ac-225 cow: application to the radiolabeling of antibodies with Bi-213. In: Emran AM, ed. Chemists' View of Imaging Centers. New York, NY: Plenum Press; 1995:315-322.
48. 4 solutions: isolation of Ac-227 from Pa-231 and Ac-227 daughters. J Chromatog. 1964;16:538-540.
49. Nikula TK, Bocchia M, Curcio MJ, et al. Impact of the high tyrosine fraction in complementarity regions: measured and predicted effects of radioiodination on IgG immunoreactivity. Mol Immunol. 1995;32:865-872.
50. Yamauchi K, Suzuki Y, Nagao T, Arimori S. Kinetics of indium-111 chloride in chronic myelogenous leukemia. Nucl Med Commun. 1989;10:817-826.
51. Durbin PW. Metabolic characteristics within a chemical family. Health Phys. 1960;2:225-238.
52. Scheinberg DA, Strand M, Gansow OA. Tumor imaging with radioactive metal chelates conjugated to monoclonal antibodies. Science. 1982;215:1511-1513.
53. Gansow OA. Newer approaches to the radiolabeling of monoclonal antibodies by use of metal chelales. Nucl Med Biol. 1991;18:369-381.
54. Gansow OA, Brechbiel MW, Pippin CG, et al. Lead and bismuth complexes of functionalized DTPA ligands and of the polyazacycloalkane-N-acetic acid DOTA. Utility for radioimmunoimaging and radioimmunotherapy. Antibody Immunoconjug Radiopharm. 1991;4:413-425.
55. Jurcic JG, Caron PC, Nikula TK, et al. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias. Cancer Res. 1995;55(suppl):5908s-5910s.
56. Zucchini GL, Friedman AM. Isotopic generator for Pb-212 and Bi-212. Int J Nucl Med Biol. 1982;9:83-84.
57. Kozak RW, Atcher RW, Gansow OA, Friedman AM, Hines JJ, Waldmann TA. Bismuth-212-labeled anti-Tac monoclonal antibody: α-particle-emitting radionuclides as modalities for radioimmunotherapy. Proc Natl Acad Sci USA. 1986;83: 474-478.
58. 2M arrest and apoptosis in murine T lymphoma cells following exposure to Bi-212 alpha particle irradiation. Nucl Med Biol. 1993;20:795-805.